

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 4

In the Claims

Please cancel claims 126 and 128 without disclaimer or prejudice to applicants' rights to pursue the subject matter of these claims in this or another application. Please amend claims 123 and 133-134 and 142 and add new claims 144-166 in the subject application as set forth below. The differences between the previously pending claims and the amended claims are shown by underlining added material and bracketing deleted material in the Version of Claims with Markings to Show Changes Made attached hereto as **Exhibit 2**.

7
C1
123. (Amended) A method of treating a mammal afflicted with an autoimmune disease comprising administering to the mammal a purified polypeptide having the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides.

108
133. (Amended) A method of treating a mammal afflicted with an autoimmune disease comprising administering to the mammal a pharmaceutical composition consisting essentially of a purified polypeptide having the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides, and a pharmaceutically acceptable carrier.

134. (Amended) The method of claim 133 wherein said autoimmune disease is a B cell mediated autoimmune disease, a T cell mediated autoimmune disease, a demyelinating disease, an inflammatory disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis,

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 5

pemphigus vulgaris, or systemic lupus erythematosus.

142. (Amended) A method of treating graft versus host disease (GVHD), host versus graft disease (HVGD) or delayed-type hypersensitivity (DTH) in a mammal comprising administering to the mammal a purified polypeptide having the amino acid sequence SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides.
